Burosumab
Crysvita (burosumab) is an antibody pharmaceutical. Burosumab was first approved as Crysvita on 2018-02-19. It has been approved in Europe to treat familial hypophosphatemia and familial hypophosphatemic rickets. The pharmaceutical is active against fibroblast growth factor 23.
Trade Name | Crysvita |
---|---|
Common Name | Burosumab |
Indication | familial hypophosphatemia, familial hypophosphatemic rickets |
Drug Class | Monoclonal antibodies: fully human, bone target |
